Fundz
You are reading one round. Fundz also knows which of your own LinkedIn connections can open this account.See it live →

Orvida Pharma secures interim financing led by Recordati to advance ontivatrep development for rare genetic skin diseases.

PRIVATESep 15, 2026•1 day ago

Round Type

Venture - Series Unknown

Center DistrictBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma

Investors

Recordati

Description

Orvida Pharma has announced the completion of an interim financing led by Recordati. This financing will support the continued clinical development of ontivatrep, an oral TRPV3 inhibitor. Additional resources will also aim to advance Orvida’s broader pipeline of programs targeting rare genetic skin diseases. The involvement of Recordati strengthens Orvida's ability to reach important clinical milestones.

Company Information

Company

Orvida Pharma

Location

Center District, Israel

About

Orvida Pharma is a clinical-stage biotechnology company developing first- and best-in-class treatments for rare and severe genetic skin diseases. Their lead investigational candidate, ontivatrep, is a novel, highly specific, and selective oral TRPV3 inhibitor being developed for the treatment of Olmsted syndrome, severe keratodermas, and ichthyosis. The management team comprises industry leaders with deep expertise in drug discovery, dermatological pharmaceutical development, and rare disease therapeutics.

Don't miss Orvida Pharma's next move

Get an email the moment Orvida Pharma raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Orvida Pharma's next move

See what Strategic adds

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Orvida Pharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.